​

Tourmaline Bio (TRML) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TRML Stock Forecast

Tourmaline Bio (TRML) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $47.90, with a high of $48.00 and a low of $47.50. This represents a -0.17% decline from the last price of $47.98.

$10 $18 $26 $34 $42 $50 High: $48 Avg: $47.9 Low: $47.5 Last Closed Price: $47.98

TRML Stock Rating

Tourmaline Bio stock's rating consensus is Hold, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (10.00%), 9 Hold (90.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 10 0 9 1 Strong Sell Sell Hold Buy Strong Buy

TRML Price Target Upside V Benchmarks

TypeNameUpside
StockTourmaline Bio-0.17%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-58
Avg Price Target-$47.90$47.69
Last Closing Price$47.98$47.98$47.98
Upside/Downside--0.17%-0.60%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-18--9
Sep, 2529---11
Aug, 2529---11
Jul, 2538---11
Jun, 2538---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2025Yi ChenH.C. Wainwright$48.00$47.610.82%0.04%
Mar 14, 2025H.C. Wainwright$50.00$18.80165.96%4.21%
Mar 06, 2025Wedbush$42.00$14.33193.09%-12.46%
Dec 05, 2024Etzer DaroutBMO Capital$50.00$24.03108.07%4.21%
Mar 21, 2024Yatin SunejaGuggenheim$50.00$28.6174.76%4.21%
Mar 20, 2024Robyn KarnauskasTruist Financial$74.00$44.6765.66%54.23%
Mar 20, 2024Roger SongJefferies$72.00$44.6761.18%50.06%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 14, 2025BMO CapitalOutperformMarket Performdowngrade
Sep 11, 2025Piper SandlerOverweightNeutraldowngrade
Sep 10, 2025H.C. WainwrightNeutraldowngrade
Sep 09, 2025GuggenheimBuyNeutraldowngrade
Sep 09, 2025WedbushOutperformNeutraldowngrade
Mar 06, 2025WedbushOutperforminitialise
Dec 05, 2024BMO CapitalOutperforminitialise
Nov 04, 2024GuggenheimBuyBuyhold
Oct 15, 2024Cantor FitzgeraldOverweightinitialise
Sep 04, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.87$-2.89----
Avg Forecast$-3.70$-2.92$-3.52$-4.49$-4.49$-3.90
High Forecast$-2.49$-2.74$-1.78$-3.49$-2.97$-3.90
Low Forecast$-4.68$-3.49$-4.54$-5.75$-7.70$-3.90
Surprise %139.73%-1.03%----

Revenue Forecast

$5M $17M $29M $41M $53M $65M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$8.57M$10.00M$10.00M$61.10M
High Forecast--$8.57M$10.00M$10.00M$61.10M
Low Forecast--$8.57M$10.00M$10.00M$61.10M
Surprise %------

Net Income Forecast

$-75M $-61M $-47M $-33M $-19M $-5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.12M$-73.21M----
Avg Forecast$-17.03M$-14.80M$-14.99M$-21.92M$-25.32M$-18.51M
High Forecast$-11.84M$-13.02M$-8.43M$-16.56M$-14.11M$-18.51M
Low Forecast$-22.23M$-16.58M$-21.56M$-27.28M$-36.54M$-18.51M
Surprise %147.29%394.70%----

TRML Forecast FAQ

Is Tourmaline Bio stock a buy?

Tourmaline Bio stock has a consensus rating of Hold, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Tourmaline Bio is a neutral investment for most analysts.

What is Tourmaline Bio's price target?

Tourmaline Bio's price target, set by 10 Wall Street analysts, averages $47.9 over the next 12 months. The price target range spans from $47.5 at the low end to $48 at the high end, suggesting a potential -0.17% change from the previous closing price of $47.98.

How does Tourmaline Bio stock forecast compare to its benchmarks?

Tourmaline Bio's stock forecast shows a -0.17% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Tourmaline Bio over the past three months?

  • October 2025: 0% Strong Buy, 11.11% Buy, 88.89% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 18.18% Strong Buy, 81.82% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 18.18% Strong Buy, 81.82% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Tourmaline Bio’s EPS forecast?

Tourmaline Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.52, marking a 21.80% increase from the reported $-2.89 in 2024. Estimates for the following years are $-4.49 in 2026, $-4.49 in 2027, and $-3.9 in 2028.

What is Tourmaline Bio’s revenue forecast?

Tourmaline Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $8.57M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $10M, followed by $10M for 2027, and $61.1M for 2028.

What is Tourmaline Bio’s net income forecast?

Tourmaline Bio's net income forecast for the fiscal year ending in December 2025 stands at $-14.994M, representing a -79.52% decrease from the reported $-73.21M in 2024. Projections indicate $-21.918M in 2026, $-25.322M in 2027, and $-18.505M in 2028.